IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0064275.html
   My bibliography  Save this article

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

Author

Listed:
  • Lixian Zhong
  • Vickie Pon
  • Sandy Srinivas
  • Nicole Nguyen
  • Meghan Frear
  • Sherry Kwon
  • Cynthia Gong
  • Robert Malmstrom
  • Leslie Wilson

Abstract

Background: Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Excellence (NICE) preliminary recommendations were negative for both abiraterone (now positive in final recommendation) and cabazitaxel (negative in final recommendation). Objective: To evaluate the cost-effectiveness of abiraterone, cabazitaxel, mitoxantrone and prednisone for mCRPC treatment in US. Methods: A decision-tree model was constructed to compare the two mCRPC treatments versus two placebos over 18 months from a societal perspective. Chance nodes include baseline pain as a severity indicator, grade III/IV side-effects, and survival at 18 months. Probabilities, survival and health utilities were from published studies. Model cost inputs included drug treatment, side-effect management and prevention, radiation for pain, and death associated costs in 2010 US dollars. Results: Abiraterone is a cost-effective choice at $94K/QALY (quality adjusted life years) compared to placebo in our base-case analysis. Cabazitaxel and abiraterone are the most effective, yet also most expensive agents. The incremental cost-effectiveness ratios (ICER) at base-case are $101K/QALY (extended dominated) for mitoxantrone vs. placebo, $91K/QALY for abiraterone vs. mitoxantrone, $956K/QALY for cabazitaxel vs. abiraterone. Abiraterone becomes less cost-effective as its AWP increases, or if the cost of mitoxantrone side-effect management decreases. Increases in the percentage of patients with baseline pain leads to an increased ICER for both mitoxantrone and abiraterone, but mitoxantrone does relatively better. Cabazitaxel remains not cost-effective. Conclusion: Our base case model suggests that abiraterone is a cost-effective option in docetaxel-refractory mCRPC patients. Newer treatments will also need a CEA assessment compared to abiraterone.

Suggested Citation

  • Lixian Zhong & Vickie Pon & Sandy Srinivas & Nicole Nguyen & Meghan Frear & Sherry Kwon & Cynthia Gong & Robert Malmstrom & Leslie Wilson, 2013. "Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-11, May.
    • Handle: RePEc:plo:pone00:0064275
    DOI: 10.1371/journal.pone.0064275
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0064275
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0064275&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0064275?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
    2. Joanna Siegel & George Torrance & Louise Russell & Bryan Luce & Milton Weinstein & Marthe Gold, 1997. "Guidelines for Pharmacoeconomic Studies," PharmacoEconomics, Springer, vol. 11(2), pages 159-168, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Fischer, Barbara & Telser, Harry & Zweifel, Peter & von Wyl, Viktor & Beck, Konstantin & Weber, Andreas, 2023. "The value of a QALY towards the end of life and its determinants: Experimental evidence," Social Science & Medicine, Elsevier, vol. 326(C).
    2. Ziebarth, Nicolas R. & Schmitt, Maike & Karlsson, Martin, 2013. "The Short-Term Population Health Effects of Weather and Pollution: Implications of Climate Change," IZA Discussion Papers 7875, Institute of Labor Economics (IZA).
    3. Maria Rubio-Valera & María Teresa Peñarrubia-María & Maria Iglesias-González & Martin Knapp & Paul McCrone & Marta Roig & Ramón Sabes-Figuera & Juan V. Luciano & Juan M. Mendive & Ana Gabriela Murruga, 2019. "Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 703-713, July.
    4. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    5. Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.
    6. Ava A John-Baptiste & Wei Wu & Paula Rochon & Geoffrey M Anderson & Chaim M Bell, 2013. "A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
    7. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    8. Bärnighausen, Till & Bloom, David E., 2009. ""Conditional scholarships" for HIV/AIDS health workers: Educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa," Social Science & Medicine, Elsevier, vol. 68(3), pages 544-551, February.
    9. Andrea Iannaccone & Thomas Marwick, 2015. "Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Medical Management or Surgery for Patients with Aortic Stenosis," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 29-45, February.
    10. Penny Reeves & Kim Edmunds & Christopher Levi & Longting Lin & Xin Cheng & Richard Aviv & Tim Kleinig & Kenneth Butcher & Jingfen Zhang & Mark Parsons & Andrew Bivard, 2018. "Cost-effectiveness of targeted thrombolytic therapy for stroke patients using multi-modal CT compared to usual practice," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-11, October.
    11. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
    12. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
    13. Shota Saito & Motoi Azumi & Yusuke Muneoka & Katsuhiko Nishino & Takashi Ishikawa & Yuichi Sato & Shuji Terai & Kouhei Akazawa, 2018. "Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 545-555, May.
    14. Jorge Barros-Garcia-Imhof & Andrés Jiménez-Alfonso & Inés Gómez-Acebo & María Fernández-Ortiz & Jéssica Alonso-Molero & Javier Llorca & Alejandro Gonzalez-Castro & Trinidad Dierssen-Sotos, 2022. "Perception of Medical Students on the Need for End-of-Life Care: A Q-Methodology Study," IJERPH, MDPI, vol. 19(13), pages 1-16, June.
    15. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    16. Hoa‐Thi‐Minh Nguyen & Tom Kompas & Roslyn I. Hickson, 2014. "Aid and the Control of Tuberculosis in Papua New Guinea: Is Australia's Assistance Cost‐Effective?," Asia and the Pacific Policy Studies, Wiley Blackwell, vol. 1(2), pages 364-378, May.
    17. Andrew Gallagher & Violetta Shersher & Duncan Mortimer & Helen Truby & Terry Haines, 2023. "The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 21(2), pages 225-242, March.
    18. Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei, 2019. "The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method," PharmacoEconomics - Open, Springer, vol. 3(3), pages 311-319, September.
    19. Samuel Herzog & Marian Shanahan & Peter Grimison & Anh Tran & Nicole Wong & Nicholas Lintzeris & John Simes & Martin Stockler & Rachael L. Morton, 2018. "Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis," PharmacoEconomics, Springer, vol. 36(1), pages 67-78, January.
    20. Dastan Bamwesigye, 2023. "Willingness to Pay for Alternative Energies in Uganda: Energy Needs and Policy Instruments towards Zero Deforestation 2030 and Climate Change," Energies, MDPI, vol. 16(2), pages 1-21, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0064275. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.